Preparation method of degradable multifunctional bone cement
A degradable multifunctional bone cement with sustained antibiotic release and osteoconductivity addresses the challenges of biofilm eradication and bone integration in treating bone infections, enhancing treatment efficacy and reducing recurrence.
Patent Information
- Application Number
- CN202411205409.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-30
- Publication Date
- 2024-12-03
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
Current treatments for bone infections, particularly those caused by open fractures, face challenges in effectively eradicating bacterial biofilms due to the non-degradability of PMMA bone cement, inconsistent antibiotic release, and lack of standardized evaluation of anti-infection and bone integration properties.
A method for preparing a degradable multifunctional bone cement using porous biphasic calcium phosphate particles loaded with vancomycin and mixed with calcium sulfate, allowing for sustained antibiotic release and promoting new bone formation.
The bone cement provides a controlled antibiotic release, matches degradation with new bone formation, and enhances osteoconductivity and osteoinductivity, improving treatment efficacy and reducing infection recurrence.
Smart Images

Figure CN119055830A_ABST
Abstract
Description
Technical Field
[0001] The invention relates to the technical field of bone infection, in particular to a method for preparing degradable multifunctional bone cement. Background Art
[0002] Bone infection is a common complication of open fractures. It is difficult to treat, has a long course of disease, and has a poor prognosis. It is currently a hot topic in trauma orthopedics. Among them, the incidence of bone infection caused by open fractures of the limbs is high, and it often leads to infected bone defects, which seriously affects the quality of life of patients.
[0003] The formation of biofilm is one of the reasons why bone infection is difficult to treat, and the most common bacteria is Staphylococcus aureus. Biofilm is a matrix composed of polysaccharides, proteins, extracellular DNA, and host components wrapped in bacterial communities. Once the biofilm matures after 6-10 weeks, the bacteria surviving in the biofilm can effectively cope with the negative impact of the surrounding environment on their proliferation and escape the host immune system. At the same time, the biofilm will also hinder the penetration of antimicrobial drugs.
[0004] At present, the main obstacle to the clinical treatment of device-related infections is the eradication of bacterial biofilms. To address this problem, the technologies currently used for prevention and treatment mainly include: local antibiotic sustained release and application of new antimicrobial drugs, surface modification of implants, and allogeneic bone transplantation. The classic method for treating infected defects: antibiotic treatment after thorough debridement, including local application of antibiotics (coating of implants with antibiotic-loaded polymethyl methacrylate, i.e. PMMA)) and systemic application of antibiotics; under the premise of infection control, sufficient mechanical support is provided to the fracture ends by external fixation and / or internal fixation. However, PMMA is non-degradable and lacks bone integration, and the local loading of antibiotics is based solely on the surgeon's experience, without quantifying the slow release of antibiotics in vivo. At present, there is no commercial multifunctional bone cement on the market, and the addition of antimicrobial drugs is entirely dependent on the surgeon's experience, which results in inconsistent standards and the inability to uniformly and effectively evaluate the anti-infection, bone integration, and degradability properties of bone cement. Summary of the invention
[0005] The purpose of the present invention is to provide a method for preparing a degradable multifunctional bone cement to solve the problems raised in the above-mentioned background technology, and effectively solve the problems of fracture end stability, intramedullary space occupation, sustained release of antibiotics to prevent infection, promotion of new bone formation, and degradability of material matrix.
[0006] To achieve the above object, the present invention provides the following technical solution: a method for preparing a degradable multifunctional bone cement, comprising the following steps:
[0007] S1: Preparation of porous biphasic calcium phosphate (BCP) particles;
[0008] S2: Preparation of vancomycin-loaded BCP particles;
[0009] S3: Mixing the BCP granules capable of sustained-release of vancomycin and the α-CSH powder mixed with vancomycin.
[0010] Preferably, hydroxyapatite (HAP) and β-tricalcium phosphate (β-TCP) are fully mixed, and then a foaming agent is added for foaming, the foaming agent and the HAP@β-TCP mixture are fully mixed, the foaming process is carried out in a microwave oven for 2 minutes, and then dried in an oven, and then calcined at a temperature of 1100° C. for 2 hours;
[0011] Finally, BCP particles are obtained after grinding and sieving.
[0012] Preferably, the ground porous biphasic calcium phosphate (BCP) is sieved sequentially with 30-mesh and 50-mesh standard sieves to obtain BCP particles with a particle size range of 300 μm-500 μm.
[0013] Preferably, the mass ratio of hydroxyapatite (HAP) to β-tricalcium phosphate (β-TCP) is:
[0014] m(HAP):m(β-TCP)≥1;
[0015] The foaming agent components include: 0.2% (w / v) methyl cellulose (MC) solution, 0.4% (w / v) polyethylene glycol (PEG) solution, 0.4% (w / v) polyvinyl alcohol (PVA) solution, and 6% (v / v) hydrogen peroxide (H2O2) solution.
[0016] Preferably, first, deionized water is used as a solvent to prepare a vancomycin solution with a concentration of 5 mg / ml, and the BCP particles are added thereto. The mixture is stirred at 200 rpm / min by a magnetic stirrer at room temperature (25° C.) and normal pressure for 7 hours, and then the drug-loaded BCP particles are vacuum freeze-dried for more than 8 hours.
[0017] A 2.5% (w / v) PLGA (75:25, MW: 66,000-107,000) acetone solution was stirred at 500 rpm / min for 30 min at room temperature and pressure by a magnetic stirrer to allow the polymer film to better adapt to the particle surface;
[0018] The wet sample was spread repeatedly on a glass disk with a stainless steel spatula until the acetone was completely evaporated at room temperature to prevent the BCP particles from agglomerating.
[0019] Preferably, α-CSH powder mixed with 5% (w / w) vancomycin is thoroughly mixed with PLGA-encapsulated drug-loaded BCP particles at a ratio of 65:35 (w / w);
[0020] Then, deionized water was added drop by drop into the drug-loaded α-CSH@BCP at a solid-liquid ratio of 2:1, mixed thoroughly, and filled into the infected bone defect that had been fully debrided. After it solidified at room temperature and normal pressure, the wound was sutured layer by layer.
[0021] Preferably, calcium phosphate bone cement and calcium sulfate bone cement are blended in a ratio of 35:65 before use.
[0022] The present invention has at least the following beneficial effects:
[0023] 1. First, the bone cement matrix is a calcium sulfate-calcium phosphate complex. After implantation, it follows a clear release curve and slowly releases antibiotics for 6 weeks, which can effectively inhibit bacteria from forming biofilms. Second, the degradation rate of the calcium sulfate-calcium phosphate complex in vivo matches the rate of local new bone formation. Third, the bone cement matrix has ideal osteoconductivity and osteoinductivity, which is conducive to the healing of nonunion.
[0024] 2. Commercial production to achieve personalized precision treatment; bone cement has good biocompatibility, which improves the anti-infection treatment effect and reduces the probability of recurrence. BRIEF DESCRIPTION OF THE DRAWINGS
[0025] Figure 1 It is a schematic diagram of the overall process framework in the present invention. DETAILED DESCRIPTION
[0026] The following will be combined with the drawings in the embodiments of the present invention to clearly and completely describe the technical solutions in the embodiments of the present invention. Obviously, the described embodiments are only part of the embodiments of the present invention, not all of the embodiments. Based on the embodiments of the present invention, all other embodiments obtained by ordinary technicians in this field without creative work are within the scope of protection of the present invention.
[0027] See also Figure 1 , one of the embodiments of the present invention, prepares porous biphasic calcium phosphate (BCP) particles;
[0028] Preparation steps of BCP: Mix hydroxyapatite (HAP) and β-tricalcium phosphate (β-TCP) in a certain mass ratio → Add foaming agent for foaming → Dry in an oven → Calcinate at high temperature (1100℃, 2h). m(HAP):m(β-TCP)≥1. The foaming agent ingredients include: 0.2% (w / v) methylcellulose (MC) solution, 0.4% (w / v) polyethylene glycol (PEG) solution, 0.4% (w / v) polyvinyl alcohol (PVA) solution, 6% (v / v) hydrogen peroxide (H2O2) solution. The foaming agent is fully mixed with the HAP@β-TCP mixture. The foaming process is carried out in a microwave oven for 2min. After foaming, it is thoroughly dried in an oven.
[0029] After grinding and sieving, BCP particles are obtained: the ground BCP is sieved with 30-mesh and 50-mesh standard sieves in turn to obtain BCP particles with a particle size range of 300 μm-500 μm.
[0030] In one embodiment of the present invention, vancomycin-loaded BCP particles encapsulated by poly(lactic-co-glycolic acid) (PLGA) are prepared;
[0031] The prepared BCP particles were used to adsorb vancomycin: deionized water was used as the solvent to prepare a 5 mg / ml vancomycin solution, and the BCP particles were added. The mixture was stirred at 200 rpm / min by a magnetic stirrer at room temperature (25°C) and normal pressure for 7 hours. The drug-loaded BCP particles were then freeze-dried in a vacuum for >8 hours.
[0032] A 2.5% (w / v) PLGA (75:25, MW: 66,000-107,000) acetone solution was stirred at 500 rpm / min for 30 min at room temperature and pressure by a magnetic stirrer to better adapt the polymer film to the particle surface. The wet sample was repeatedly spread on a glass disk with a stainless steel spatula until the acetone was completely evaporated at room temperature to prevent the BCP particles from agglomerating.
[0033] In one embodiment of the present invention, deionized water is used to mix the vancomycin-loaded BCP particles with α-calcium sulfate hemihydrate (α-CSH) powder mixed with vancomycin according to a certain solid-liquid ratio;
[0034] α-CSH powder mixed with 5% (w / w) vancomycin was mixed with PLGA-encapsulated drug-loaded BCP particles at a ratio of 65:35 (w / w). Deionized water was dripped into the drug-loaded α-CSH@BCP drop by drop at a solid-liquid ratio of 2:1 and mixed thoroughly. It was allowed to solidify at room temperature and atmospheric pressure.
[0035] In the traditional treatment of bone defects, autologous bone transplantation is the gold standard for all bone transplantation surgeries due to its ideal osteoconductivity, osteoinductivity and biocompatibility. However, autologous bone transplantation also has obvious disadvantages, such as limited supply and donor site complications. Synthetic bone substitutes have solved the above problems well.
[0036] Calcium sulfate and calcium phosphate bone cements are ideal substitutes for autologous bone due to their excellent in vivo degradability and osteoconductivity. At the same time, they can also be used as carriers of antibacterial drugs to fight bone infection.
[0037] Calcium sulfate has been used as a bone graft material since 1892 as a biodegradable bioceramic graft with the characteristics of fast absorption rate and good biocompatibility. However, calcium sulfate degrades very quickly in water, lasting about 6-12 weeks, and therefore cannot provide sufficient structural support for bone ingrowth.
[0038] Calcium sulfate has the characteristics of good biocompatibility and bioabsorbability. In addition, calcium phosphate is similar to the inorganic components of human bones and has the porous characteristics of micropores (diameter <100μm) and macropores (diameter >100μm), which improves bone conduction ability and has almost no complications when calcium phosphate is implanted in the body. However, calcium phosphate bone cement itself is relatively brittle and its degradation rate is very slow, which can reach 20 weeks or even longer in the body.
[0039] In order to overcome the disadvantage that the degradation rate of the above two bone cements in vivo does not match the rate of new bone formation, calcium phosphate bone cement and calcium sulfate bone cement are blended in a certain ratio (35:65) and then used.
[0040] It should be noted that, in this article, relational terms such as first and second, etc. are only used to distinguish one entity or operation from another entity or operation, and do not necessarily require or imply any such actual relationship or order between these entities or operations. Moreover, the terms "include", "comprise" or any other variants thereof are intended to cover non-exclusive inclusion, so that a process, method, article or device including a series of elements includes not only those elements, but also other elements not explicitly listed, or also includes elements inherent to such process, method, article or device.
[0041] While the embodiments of the present invention have been shown and described, it will be appreciated by those skilled in the art that many changes, modifications, substitutions and variations can be made to the embodiments without departing from the principles and spirit of the invention.
Claims
1. A method for preparing a degradable multifunctional bone cement, characterized in that: The following steps are involved: S1: Preparation of porous biphasic calcium phosphate (BCP) particles; S2: Preparation of vancomycin-loaded BCP particles; S3: Mixing the BCP granules capable of sustained-release of vancomycin and the α-CSH powder mixed with vancomycin.
2. The method for preparing a degradable multifunctional bone cement according to claim 1, characterized in that: The method comprises the following steps: mixing hydroxyapatite (HAP) and β-tricalcium phosphate (β-TCP) thoroughly, and then adding a foaming agent to perform foaming. The foaming agent and the HAP@β-TCP mixture are fully mixed, and the foaming process is performed in a microwave oven for 2 minutes, followed by drying in an oven, and then calcining at a temperature of 1100°C for 2 hours. Finally, BCP particles are obtained after grinding and sieving.
3. The method for preparing a degradable multifunctional bone cement according to claim 2, characterized in that: The ground porous biphasic calcium phosphate (BCP) is sieved with 30-mesh and 50-mesh standard sieves in turn to obtain BCP particles with a particle size range of 300 μm-500 μm.
4. The method for preparing a degradable multifunctional bone cement according to claim 2, characterized in that: in, The mass ratio of hydroxyapatite (HAP) to β-tricalcium phosphate (β-TCP) is: m(HAP):m(β-TCP)≥1; The foaming agent components include: 0.2% (w / v) methyl cellulose (MC) solution, 0.4% (w / v) polyethylene glycol (PEG) solution, 0.4% (w / v) polyvinyl alcohol (PVA) solution, and 6% (v / v) hydrogen peroxide solution.
5. The method for preparing a degradable multifunctional bone cement according to claim 1, characterized in that: First, deionized water was used as a solvent to prepare a 5 mg / ml vancomycin solution, and the BCP particles were added. The solution was stirred at 200 rpm / min by a magnetic stirrer at room temperature (25°C) and normal pressure for 7 hours, and then the drug-loaded BCP particles were vacuum freeze-dried for more than 8 hours. A 2.5% (w / v) PLGA (75:25, MW: 66,000-107,000) acetone solution was stirred at 500 rpm / min for 30 min at room temperature and pressure by a magnetic stirrer to allow the polymer film to better adapt to the particle surface; The wet sample was spread repeatedly on a glass disk with a stainless steel spatula until the acetone was completely evaporated at room temperature to prevent the BCP particles from agglomerating.
6. The method for preparing a degradable multifunctional bone cement according to claim 5, characterized in that: α-CSH powder mixed with 5% (w / w) vancomycin was thoroughly mixed with PLGA-encapsulated drug-loaded BCP particles at a ratio of 65:35 (w / w); Then, deionized water was added drop by drop into the drug-loaded α-CSH@BCP at a solid-liquid ratio of 2:1, mixed thoroughly, and filled into the infected bone defect that had been fully debrided. After it solidified at room temperature and normal pressure, the wound was sutured layer by layer.
7. The method for preparing a degradable multifunctional bone cement according to claim 5, characterized in that: Calcium phosphate bone cement and calcium sulfate bone cement are blended in a ratio of 35:65 before use.
Citation Information
Patent Citations
Method for preparation of controlled pore size biphasic calcium phosphate composite ceramic scaffold
CN105288740A
Construction of calcium sulfate / PMMA double-carrier drug delivery system based on in-vitro study
CN111437379A
Osteoconductive matrices comprising calcium phosphate particles and statins and methods of using the same
US20120107383A1
